Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Metabolomic profiling to develop blood biomarkers for Parkinson's disease.

Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS, Flint Beal M.

Brain. 2008 Feb;131(Pt 2):389-96. doi: 10.1093/brain/awm304.

PMID:
18222993
2.

Plasma and urinary HPLC-ED determination of the ratio of 8-OHdG/2-dG in Parkinson's disease.

Bolner A, Pilleri M, De Riva V, Nordera GP.

Clin Lab. 2011;57(11-12):859-66.

PMID:
22239015
3.

Increased oxidative damage in peripheral blood correlates with severity of Parkinson's disease.

Chen CM, Liu JL, Wu YR, Chen YC, Cheng HS, Cheng ML, Chiu DT.

Neurobiol Dis. 2009 Mar;33(3):429-35. doi: 10.1016/j.nbd.2008.11.011. Epub 2008 Dec 9.

PMID:
19110057
4.

8-hydroxy-2'-deoxyguanosine of leukocyte DNA as a marker of oxidative stress in chronic hemodialysis patients.

Tarng DC, Huang TP, Wei YH, Liu TY, Chen HW, Wen Chen T, Yang WC.

Am J Kidney Dis. 2000 Nov;36(5):934-44.

PMID:
11054349
6.

3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis.

Lewitt PA, Li J, Lu M, Beach TG, Adler CH, Guo L; Arizona Parkinson's Disease Consortium.

Mov Disord. 2013 Oct;28(12):1653-60. doi: 10.1002/mds.25555. Epub 2013 Jul 19.

PMID:
23873789
7.

Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy.

Kikuchi A, Takeda A, Onodera H, Kimpara T, Hisanaga K, Sato N, Nunomura A, Castellani RJ, Perry G, Smith MA, Itoyama Y.

Neurobiol Dis. 2002 Mar;9(2):244-8.

PMID:
11895375
9.

Increased oxidative damage to peripheral blood leukocyte DNA in chronic peritoneal dialysis patients.

Tarng DC, Wen Chen T, Huang TP, Chen CL, Liu TY, Wei YH.

J Am Soc Nephrol. 2002 May;13(5):1321-30.

10.

Oxidative damage in Parkinson disease: Measurement using accurate biomarkers.

Seet RC, Lee CY, Lim EC, Tan JJ, Quek AM, Chong WL, Looi WF, Huang SH, Wang H, Chan YH, Halliwell B.

Free Radic Biol Med. 2010 Feb 15;48(4):560-6. doi: 10.1016/j.freeradbiomed.2009.11.026. Epub 2009 Dec 4.

PMID:
19969070
11.

Association between serum uric acid and motor subtypes of Parkinson's disease.

Lolekha P, Wongwan P, Kulkantrakorn K.

J Clin Neurosci. 2015 Aug;22(8):1264-7. doi: 10.1016/j.jocn.2015.02.015. Epub 2015 Jun 6.

PMID:
26055955
12.

Potential utility of autoantibodies as blood-based biomarkers for early detection and diagnosis of Parkinson's disease.

DeMarshall CA, Han M, Nagele EP, Sarkar A, Acharya NK, Godsey G, Goldwaser EL, Kosciuk M, Thayasivam U, Belinka B, Nagele RG; Parkinson’s Study Group Investigators.

Immunol Lett. 2015 Nov;168(1):80-8. doi: 10.1016/j.imlet.2015.09.010. Epub 2015 Sep 16.

13.

Low plasma uric acid level in Parkinson's disease.

Annanmaki T, Muuronen A, Murros K.

Mov Disord. 2007 Jun 15;22(8):1133-7.

PMID:
17443703
14.

Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects.

Simon DK, Simuni T, Elm J, Clark-Matott J, Graebner AK, Baker L, Dunlop SR, Emborg M, Kamp C, Morgan JC, Ross GW, Sharma S, Ravina B; NINDS NET-PD Investigators.

J Parkinsons Dis. 2015;5(4):731-6. doi: 10.3233/JPD-150666.

15.

Uric acid in Parkinson's disease.

Schlesinger I, Schlesinger N.

Mov Disord. 2008 Sep 15;23(12):1653-7. doi: 10.1002/mds.22139. Review.

PMID:
18618666
16.

A new and fast methodology to assess oxidative damage in cardiovascular diseases risk development through eVol-MEPS-UHPLC analysis of four urinary biomarkers.

Mendes B, Silva P, Mendonça I, Pereira J, Câmara JS.

Talanta. 2013 Nov 15;116:164-72. doi: 10.1016/j.talanta.2013.04.064. Epub 2013 May 3.

PMID:
24148388
17.

Plasma lipid peroxidation in sporadic Parkinson's disease. Role of the L-dopa.

Agil A, Durán R, Barrero F, Morales B, Araúzo M, Alba F, Miranda MT, Prieto I, Ramírez M, Vives F.

J Neurol Sci. 2006 Jan 15;240(1-2):31-6. Epub 2005 Oct 10.

PMID:
16219327
18.

Levodopa therapy reduces DNA damage in peripheral blood cells of patients with Parkinson's disease.

Cornetta T, Palma S, Aprile I, Padua L, Tonali P, Testa A, Cozzi R.

Cell Biol Toxicol. 2009 Aug;25(4):321-30. doi: 10.1007/s10565-008-9086-6. Epub 2008 Jun 4.

PMID:
18523852
19.

Parkinson's Disease is Accompanied by Intertwined Alterations in Iron Metabolism and Activated Immune-inflammatory and Oxidative Stress Pathways.

de Farias CC, Maes M, Bonifacio KL, Matsumoto AK, Bortolasci CC, Nogueira AS, Brinholi FF, Morimoto HK, de Melo LB, Moreira EG, Barbosa DS.

CNS Neurol Disord Drug Targets. 2017;16(4):484-491. doi: 10.2174/1871527316666170223161004.

PMID:
28240188
20.

Metabolomic biomarkers as strong correlates of Parkinson disease progression.

LeWitt PA, Li J, Lu M, Guo L, Auinger P; Parkinson Study Group–DATATOP Investigators.

Neurology. 2017 Feb 28;88(9):862-869. doi: 10.1212/WNL.0000000000003663. Epub 2017 Feb 8.

Supplemental Content

Support Center